Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey
Open Access
- 13 June 2013
- Vol. 3 (6), e002574
- https://doi.org/10.1136/bmjopen-2013-002574
Abstract
Objectives To estimate the cost of illness (COI) of individuals with self-reported adverse drug events (ADEs) from a societal perspective and to compare these estimates with the COI for individuals without ADE. Furthermore, to estimate the direct costs resulting from two ADE categories, adverse drug reactions (ADRs) and subtherapeutic effects of medication therapy (STE). Design Cross-sectional study. Setting The adult Swedish general population. Participants The survey was distributed to a random sample of 14 000 Swedish residents aged 18 years and older, of which 7099 responded, 1377 reported at least one ADE and 943 reported an ADR or STE. Main outcome measures Societal COI, including direct and indirect costs, for individuals with at least one self-reported ADE, and the direct costs for prescription drugs and healthcare use resulting from self-reported ADRs and STEs were estimated during 30 days using a bottom-up approach. Results The economic burden for individuals with ADEs were (95% CI) 442.7 to 599.8 international dollars (Int$), of which direct costs were Int$ 279.6 to 420.0 (67.1%) and indirect costs were Int$ 143.0 to 199.8 (32.9%). The average COI was higher among those reporting ADEs compared with other respondents (COI: Int$ 442.7 to 599.8 versus Int$ 185.8 to 231.2). The COI of respondents reporting at least one ADR or STE was Int$ 468.9 to 652.9. Direct costs resulting from ADRs or STEs were Int$ 15.0 to 48.4. The reported resource use occurred both in hospitals and outside in primary care. Conclusions Self-reported ADRs and STEs cause resource use both in hospitals and in primary care. Moreover, ADEs seem to be associated with high overall COI from a societal perspective when comparing respondents with and without ADEs. There is a need to further examine this relationship and to study the indirect costs resulting from ADEs.This publication has 26 references indexed in Scilit:
- Non-response in a nationwide follow-up postal survey in Finland: a register-based mortality analysis of respondents and non-respondents of the Health and Social Support (HeSSup) StudyBMJ Open, 2012
- How are the Costs of Drug-Related Morbidity Measured?Drug Safety, 2012
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Methods to assess the costs and health effects of interventions for improving health in developing countriesBMJ, 2005
- Multiplicity of medication safety terms, definitions and functional meanings: when is enough enough?Quality and Safety in Health Care, 2005
- Adverse drug events and medication errors: detection and classification methodsQuality and Safety in Health Care, 2004
- Pharmacoeconomics of adverse drug reactionsFundamental & Clinical Pharmacology, 2004
- The cost of adverse drug reactionsExpert Opinion on Pharmacotherapy, 2003
- Methodology matters. Identifying drug safety issues: from research to practiceInternational Journal for Quality in Health Care, 2000
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990